-
-
公开(公告)号:KR101865223B1
公开(公告)日:2018-06-08
申请号:KR1020110101291
申请日:2011-10-05
Applicant: 삼성전자주식회사
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00
CPC classification number: A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: 항 c-Met 인간화항체및 이를포함하는암 예방또는치료용약학적조성물에관한것이다. 일구체예에따른항 c-Met 인간화항체및 이를포함하는암 예방또는치료용약학적조성물에의하면, 암을효율적으로예방또는치료할수 있다.
-
公开(公告)号:KR1020150030829A
公开(公告)日:2015-03-23
申请号:KR1020130109889
申请日:2013-09-12
Applicant: 삼성전자주식회사
IPC: A61K47/48 , A61K39/395 , A61P35/00
CPC classification number: A61K47/6859 , A61K47/6803 , A61K47/6851 , A61K47/50 , A61K39/395
Abstract: Provided are a conjugate in which a c-Met targeting compound and a bioactive material is chemically bound, and uses of the conjugate. The c-Met targeting compound can be an anti-c-Met antibody. Also, the bioactive material can be one or more types selected from a group of a cellulotoxic drug, radioisotope, and a contrast substance. In other examples, provided is an antibody-drug conjugate (ADC) in which the anti-c-Met antibody and the cellulotoxic drug are bound.
Abstract translation: 提供了其中化学键合c-Met靶向化合物和生物活性物质的缀合物,以及缀合物的用途。 c-Met靶向化合物可以是抗c-Met抗体。 此外,生物活性物质可以是选自纤维素毒性药物,放射性同位素和对比物质的一种或多种。 在其它实施例中,提供了其中结合抗c-Met抗体和纤维素毒性药物的抗体 - 药物偶联物(ADC)。
-
-
-
-
-
公开(公告)号:KR102029137B1
公开(公告)日:2019-10-08
申请号:KR1020130032842
申请日:2013-03-27
Applicant: 삼성전자주식회사 , 사회복지법인 삼성생명공익재단
IPC: A61K39/395 , A61K31/517 , A61P35/00
-
-
10.
公开(公告)号:KR1020140117909A
公开(公告)日:2014-10-08
申请号:KR1020130032842
申请日:2013-03-27
Applicant: 삼성전자주식회사 , 사회복지법인 삼성생명공익재단
IPC: A61K39/395 , A61K31/517 , A61P35/00
CPC classification number: A61K39/3955 , A61K31/517 , A61K31/5377 , A61K31/00 , A61K2300/00
Abstract: Provided are a pharmaceutical composition comprising an EGFR antagonist and an anti-c-Met antibody as active ingredients for a combination therapy for preventing and/or treating diseases caused by c-Met or EGFR. The pharmaceutical composition for a combination therapy has an excellent synergistic effect and can exhibit the effect even when having a resistance to EGFR antagonist, thereby can more effectively perform the treatment.
Abstract translation: 提供了包含EGFR拮抗剂和抗c-Met抗体作为预防和/或治疗由c-Met或EGFR引起的疾病的组合疗法的活性成分的药物组合物。 用于组合疗法的药物组合物具有优异的协同作用,并且即使具有抗EGFR拮抗剂的抗性也能发挥作用,从而可以更有效地进行治疗。
-
-
-
-
-
-
-
-
-